Clinical Trial Update: Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

Open-label dose-finding study evaluating TRC105 in combination with capecitabine for metastatic breast cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• TRC105 (carotuximab)

Snippet

Sponsor: Tracon Pharmaceuticals Inc. | Conditions: Metastatic Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-02-26